FDA Report on CBD to Congress

Report to the U.S. House Committee on Appropriations and the U.S. Senate Committee on Appropriations on Cannabidiol (CBD) by U.S. Food and Drug Administration.

On December 20, 2019, the Further Consolidated Appropriations Act, 2020 (P.L. 116-94), was enacted into law, which provided FDA with appropriations under Division B, the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Act, 2020, for the fiscal year ending September 30, 2020. The accompanying Joint Explanatory Statement directed the Food and Drug Administration (FDA or the Agency) to report on Cannabidiol (CBD):

“Within 60 days of enactment of this Act, the FDA shall provide the Committees with a report regarding the agency’s progress toward obtaining and analyzing data to help determine a policy of enforcement discretion and the process in which CBD meeting the definition of hemp will be evaluated for use in products.”

In response to this directive, FDA prepared the following report. 18 pages.